|
... recommendations.
With respect to MMPW, Goldman Small Cap Research was been compensated by a third party in the amount of $3500 for a research subscription service.
With respect to PMCB, ...
... efficacy but what happens to the patients when they no longer respond to these therapies? With limited options currently available, PharmaCyte Biotech (OTCQB – PMCB - $0.06) is set to launch a new, ...
If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment ...
... Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since ...
... and not a sprint for biotechnology companies of all sizes. However, recent and pending events lead us to believe that the PharmaCyte Biotech (OTCQB – PMCB - $0.0875 – Spec Buy) road to approval and marketing ...
PMCB's approach to diabetes therapy could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them.
.report-main ...
Last week was an incredible week for PharmaCyte Biotech (OTC – PMCB), which prompted us to issue a new research update. Major industry and company news released last week should take investor sentiment ...
... and funding have recently turned toward utilizing encapsulation techniques to treat Type 1 diabetes (T1D), including the approach championed by PharmaCyte Biotech (OTCQB – PMCB - $0.1152 – Spec Buy), ...
Investors that overlook PharmaCyte Biotech’s (OTCQB – PMCB - $0.1035 – Spec Buy) breakthrough technology to treat diabetes may be kicking themselves in the end, given the low valuation afforded ...
PharmaCyte Biotech (OTC – PMCB) may be undervalued today but that is not likely to last. See why it could quickly return to its highs of six months ago.
.report-main h1{
color:#014e92;
font-size:30px;
}
.report-main ...
One of the untold stories behind PharmaCyte Biotech’s (OTCQB – PMCB - $0.159) success is that the formation and implementation of its International Diabetes Consortium has already resulted in ...
One of the untold stories regarding the recent transformation of PharmaCyte Biotech (OTCQB – PMCB - $0.1649 – Spec Buy) is that much of it is owed to the new leadership team. In the span of just over ...
A major scientific journal recently published a study led by one of PMCB’s Diabetes Consortium members. The animal study showed that a new cell line designed by the study’s authors have ...
It is no surprise that PharmaCyte Biotech’s (OTCQB – PMCB - $0.1226 – Spec Buy) treatment for pancreatic cancer retains such a high profile in the oncology community. After all, the Company is ...
... – PMCB - $0.1375 – Spec Buy).
The primary driver behind the rise in biotechs may be the Federal Drug Administration (FDA) itself. Last year, it approved 41 new drugs which, according to the organization’s ...
... these transactions, PharmaCyte Biotech, Inc. (OTCQB – PMCB – $0.1394 – Spec Buy) may be sitting in the catbird seat as an unusually attractive potential target.
Why?
Major pharmaceutical companies ...
... Biotech in 2015
Late last week, PharmaCyte Biotech, Inc. (OTCQB – PMCB - $0.138 – Spec Buy) announced that it was on track to commence clinical trials in the second half of 2015, milestone events that ...
It has been over a year since we have written about PharmaCyte Biotech (OTCQB – PMCB), formerly Nuvilex we believe that these shares are grossly undervalued in light of the Company’s increasingly ...
|
||
|
|
||